Drugs / Multiple Antigen Specific Endogenously derived T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04904185 | Sep 2021 → Jun 2024 | melanoma | Inge Marie Svane | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multiple Antigen Specific Endogenously derived T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04904185 ↗ |
| Known as | MASE-T | “MASE-T” NCT04904185 ↗ |
| Modality | Cell therapy | “Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells” NCT04904185 ↗ |
| Route | Intravenous | “i.v. infusion of the MASE-T product” NCT04904185 ↗ |